Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
Status:
RECRUITING
Trial end date:
2028-12-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).
Phase:
PHASE2
Details
Lead Sponsor:
R-Pharm International, LLC
Collaborators:
Data Management 365 Exacte Labs LLC Keystat, LLC R-Pharm